Literature DB >> 18325318

New strategies in the medical treatment of carotid artery disease.

Kumar Rajamani1, Seemant Chaturvedi.   

Abstract

Most patients with ischemic stroke or transient ischemic attack are screened for internal carotid artery stenosis. Although it is important to identify candidates for endarterectomy or stenting, the clinician must realize that most patients are not candidates for revascularization. Therefore, medical therapy remains the cornerstone of treatment. In this article, current thinking on medical therapy for carotid atherosclerosis is outlined, including aggressive use of statins, targeted blood pressure lowering, and antithrombotic therapy. Implementation of these therapies will likely reduce the need for revascularization procedures in the future.

Entities:  

Year:  2008        PMID: 18325318     DOI: 10.1007/s11936-008-0017-x

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  35 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  High-dose atorvastatin after stroke or transient ischemic attack.

Authors:  Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

3.  Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials.

Authors:  H C Bucher; L E Griffith; G H Guyatt
Journal:  Ann Intern Med       Date:  1998-01-15       Impact factor: 25.391

4.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.

Authors:  Allen J Taylor; Lance E Sullenberger; Hyun J Lee; Jeannie K Lee; Karen A Grace
Journal:  Circulation       Date:  2004-11-10       Impact factor: 29.690

5.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

Review 6.  Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis.

Authors:  Pierre Amarenco; Julien Labreuche; Philippa Lavallée; Pierre-Jean Touboul
Journal:  Stroke       Date:  2004-10-28       Impact factor: 7.914

Review 7.  Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Gregory W Albers; Pierre Amarenco; J Donald Easton; Ralph L Sacco; Philip Teal
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

Review 8.  Modulating atherosclerosis through inhibition or blockade of angiotensin.

Authors:  Robert S Rosenson
Journal:  Clin Cardiol       Date:  2003-07       Impact factor: 2.882

9.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.

Authors:  James F Toole; M René Malinow; Lloyd E Chambless; J David Spence; L Creed Pettigrew; Virginia J Howard; Elizabeth G Sides; Chin-Hua Wang; Meir Stampfer
Journal:  JAMA       Date:  2004-02-04       Impact factor: 56.272

10.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

Authors:  Steven E Nissen; E Murat Tuzcu; Paul Schoenhagen; B Greg Brown; Peter Ganz; Robert A Vogel; Tim Crowe; Gail Howard; Christopher J Cooper; Bruce Brodie; Cindy L Grines; Anthony N DeMaria
Journal:  JAMA       Date:  2004-03-03       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.